Dec 21 |
Spironolactone reduces COVID-19 risk: real-time meta analysis of 12 studies | |
| Significantly lower risk is seen for mortality, progression, and recovery. 11 studies from 10 independent teams in 8 countries show significant benefit. Meta analysis using the most serious outcome reported shows 31% [15‑44%] l.. | ||
Dec 18 2023 |
et al., Frontiers in Public Health, doi:10.3389/fpubh.2023.1280434 | Drug prescription patterns and their association with mortality and hospitalization duration in COVID-19 patients: insights from big data |
| 32% lower mortality (p<0.0001). Retrospective study of 917,198 hospitalized COVID-19 cases covered by the Iran Health Insurance Organization over 26 months showing that antithrombotics, corticosteroids, and antivirals reduced mortality while diuretics, antibiotics, and.. | ||
Mar 2 2023 |
et al., medRxiv, doi:10.1101/2023.02.28.23286515 | Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study |
| 18% lower mortality (p=0.004) and 17% lower ventilation (p<0.0001). PSM retrospective 898,303 hospitalized COVID-19 patients in the USA, 16,324 on spironolactone, showing lower mortality and ventilation with spironolactone use. | ||
Jul 6 2022 |
et al., Cell Reports Methods, doi:10.1016/j.crmeth.2023.100503 (date from preprint) | Integrative analysis of functional genomic screening and clinical data identifies a protective role for spironolactone in severe COVID-19 |
| 81% lower ventilation (p=0.006) and 66% lower ICU admission (p=0.002). PSM retrospective 64,349 COVID-19 patients in the USA, showing spironolactone associated with lower ICU admission. Authors also present In Vitro research showing dose-dependent inhibition in a human lung epithelial cell line. | ||
Jul 2 2022 |
et al., medRxiv, doi:10.1101/2022.07.01.22277163 | Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi |
| 72% lower progression (p=0.03), 49% higher hospital discharge (p=0.05), and 18% faster recovery (p=0.06). RCT 120 hospitalized patients in India, 74 treated with spironolactone and dexamethasone, and 46 with dexamethasone, showing lower progression with treatment. Spironolactone 50mg once daily day 1, 25mg once daily until day 21. | ||
Mar 29 2022 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 | Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications |
| 7% fewer cases (p=0.008). Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing lower cases with chronic use of spironolactone. | ||
Feb 7 2022 |
et al., Journal of the Endocrine Society, doi:10.1210/jendso/bvac017 | A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19 |
| 55% lower mortality (p=0.1), 34% lower ventilation (p=0.36), 19% lower ICU admission (p=0.67), and 47% improved recovery (p<0.0001). RCT including 51 spironolactone patients and 87 control patients in Iran, showing improved recovery with spironolactone, sitagliptin, and the combination of both. | ||
Jan 21 2022 |
et al., Journal of Endocrinological Investigation, doi:10.1007/s40618-023-02141-0 (date from preprint) | Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study |
| 78% lower hospitalization (p=0.0008), 67% lower progression (p=0.003), and 64% faster recovery (p=0.0001). Prospective study of 206 outpatients in Iran, 103 treated with spironolactone and sitagliptin, showing lower hospitalization and faster recovery with treatment. spironolactone 100mg and sitagliptin 100mg daily. | ||
Oct 13 2021 |
et al., Aydin Sağlik Dergi̇si̇, doi:10.17932/IAU.ASD.2015.007/asd_v07i3002 | Assessment Of The Efficacy Of Spironolactone For COVID-19 ARDS Patients |
| 46% lower mortality (p=0.002). Retrospective 30 COVID-19 ARDS ICU patients and 30 control patients, showing lower mortality with treatment. | ||
Feb 23 2021 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2021.629176 | Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea |
| 77% fewer cases (p=0.005). Retrospective 6,462 liver cirrhosis patients in South Korea, with 67 COVID+ cases, showing significantly lower cases with spironolactone treatment. Death and ICU results per group are not provided. | ||
Dec 3 2020 |
et al., Кардиология, doi:10.18087/cardio.2020.11.n1440 | Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT) |
| 11% improved recovery (p=0.47), 8% shorter hospitalization (p=0.35), and 87% improved viral clearance (p=0.08). Prospective 103 PCR+ patients in Russia, 33 treated with bromexhine+spironolactone, showing lower PCR+ at day 10 or hospitalization >10 days with treatment. Bromhexine 8mg 4 times daily, spironolactone 25-50 mg/day for 10 days. | ||
Oct 6 2020 |
et al., medRxiv, doi:10.1101/2020.10.05.20206870 | An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial |
| 77% faster recovery (p=0.006) and 38% faster viral clearance (p=0.02). Prospective study of 270 female COVID-19 patients in Brazil, 75 with hyperandrogenism, of which 8 were on spironolactone. Results suggest that HA patients may be at increased risk, and that spironolactone use may reduce the risk compared .. | ||
May 7 2020 |
et al., Journal of Hypertension, doi:10.1097/hjh.0000000000002515 | Influence of inhibitors of the renin–angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients |
| 129% higher combined mortality/ICU admission (p=0.0007). Retrospective 689 hospitalized COVID-19 patients in Denmark, showing higher risk of ICU/death with spironolactone use in unadjusted results subject to confounding by indication. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.